​

Elevation Oncology (ELEV) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

ELEV Stock Forecast

Elevation Oncology (ELEV) stock forecast, based on 10 Wall Street analysts, predicts a 12-month average price target of $9.00, with a high of $10.00 and a low of $8.00. This represents a 2627.27% increase from the last price of $0.33.

- $2 $4 $6 $8 $10 High: $10 Avg: $9 Low: $8 Last Closed Price: $0.33

ELEV Stock Rating

Elevation Oncology stock's rating consensus is Buy, based on 10 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 5 Buy (50.00%), 4 Hold (40.00%), 1 Sell (10.00%), and 0 Strong Sell (0.00%).

Buy
Total 10 0 1 4 5 Strong Sell Sell Hold Buy Strong Buy

ELEV Price Target Upside V Benchmarks

TypeNameUpside
StockElevation Oncology2627.27%
SectorHealthcare Stocks 33.91%
IndustryBiotech Stocks 83.49%

Price Target Trends

1M3M12M
# Anlaysts--2
Avg Price Target--$9.00
Last Closing Price$0.33$0.33$0.33
Upside/Downside--2627.27%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 25125--8
Mar, 2535---8
Feb, 2535---8
Jan, 2535---8
Dec, 2434---7
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 31, 2024Biren AminPiper Sandler$10.00$4.07145.70%2930.30%
May 13, 2024Sudan LoganathanStephens$8.00$3.54125.99%2324.24%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 21, 2025CitigroupMarket Performdowngrade
Mar 20, 2025WedbushNeutraldowngrade
Jan 03, 2025William BlairOutperforminitialise
Aug 06, 2024Cowen & Co.BuyBuyhold
Jun 28, 2024Cowen & Co.BuyBuyhold
Jun 28, 2024Piper SandlerOverweightOverweighthold
Jun 03, 2024Piper SandlerOverweightOverweighthold
May 31, 2024Piper SandlerOverweightinitialise
May 13, 2024StephensOverweightinitialise
May 30, 2023Telsey AdvisoryOutperformupgrade

Financial Forecast

EPS Forecast

Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.34$-0.78----
Avg Forecast$-1.44$-0.85$-0.88$-0.93$-1.10$-0.72
High Forecast$-1.43$-0.82$-0.77$-0.56$-0.59$-0.72
Low Forecast$-1.45$-0.87$-0.94$-1.30$-1.79$-0.72
Surprise %-6.94%-8.24%----

Revenue Forecast

$10M $21M $32M $43M $54M $65M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast----$10.87M$60.71M
High Forecast----$10.87M$60.71M
Low Forecast----$10.87M$60.71M
Surprise %------

Net Income Forecast

$-65M $-55M $-45M $-35M $-25M $-15M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-45.70M$-44.48M----
Avg Forecast$-48.94M$-28.67M$-29.17M$-31.68M$-40.56M$-24.65M
High Forecast$-48.60M$-27.82M$-26.34M$-18.94M$-20.04M$-24.65M
Low Forecast$-49.28M$-29.53M$-32.00M$-44.42M$-61.09M$-24.65M
Surprise %-6.60%55.14%----

ELEV Forecast FAQ

Is Elevation Oncology stock a buy?

Elevation Oncology stock has a consensus rating of Buy, based on 10 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 5 Buy, 4 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Elevation Oncology is a favorable investment for most analysts.

What is Elevation Oncology's price target?

Elevation Oncology's price target, set by 10 Wall Street analysts, averages $9 over the next 12 months. The price target range spans from $8 at the low end to $10 at the high end, suggesting a potential 2627.27% change from the previous closing price of $0.33.

How does Elevation Oncology stock forecast compare to its benchmarks?

Elevation Oncology's stock forecast shows a 2627.27% upside, outperforming the average forecast for the healthcare stocks sector (33.91%) and outperforming the biotech stocks industry (83.49%).

What is the breakdown of analyst ratings for Elevation Oncology over the past three months?

  • April 2025: 12.50% Strong Buy, 25.00% Buy, 62.50% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 37.50% Strong Buy, 62.50% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 37.50% Strong Buy, 62.50% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Elevation Oncology’s EPS forecast?

Elevation Oncology's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.88, marking a 12.82% increase from the reported $-0.78 in 2024. Estimates for the following years are $-0.93 in 2026, $-1.1 in 2027, and $-0.72 in 2028.

What is Elevation Oncology’s revenue forecast?

Elevation Oncology's average annual revenue forecast for its fiscal year ending in December 2025 is $0, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $0, followed by $10.87M for 2027, and $60.71M for 2028.

What is Elevation Oncology’s net income forecast?

Elevation Oncology's net income forecast for the fiscal year ending in December 2025 stands at $-29.171M, representing a -34.43% decrease from the reported $-44.485M in 2024. Projections indicate $-31.683M in 2026, $-40.563M in 2027, and $-24.649M in 2028.